Optivo Finance PLC Publication of a Prospectus (2336E)

TIDM20SY

RNS Number : 2336E

Optivo Finance PLC

09 March 2022

Publication of Prospectus

Optivo Finance plc

9 March 2022

Optivo previously announced on 17 September 2020 that it had raised GBP150 million of long-term funding on an 18 month deferred settlement basis to refinance its Bank of England Covid Corporate Financing Facility utilisation.

Optivo arranged the funding via a GBP150 million (notional amount) tap of its existing 5.25% 2043 bonds (the Tap Issue), of which it then agreed a forward sale of GBP100 million (notional amount) at a price of 150.7 per cent for settlement in March 2022, so raising GBP150 million proceeds. Optivo retained GBP50 million (notional amount) of the increased bond for potential sale to be agreed at a future date.

In respect of the Tap Issue, the following prospectus (the Prospectus) has been approved by the Financial Conduct Authority and is available for viewing:

Optivo Finance plc

GBP150,000,000 5.25per cent. Secured Bonds due 2043

(to be consolidated and form a single series with the existing GBP150,000,000 5.25 per cent. Secured Bonds due 2043)

To view the full document, please paste the following URL into the address bar of your browser.

http://www.rns-pdf.londonstockexchange.com/rns/2336E_1-2022-3-9.pdf

A copy of the above Prospectus will also be submitted to the National Storage Mechanism and will be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

For further information, please visit https://www.optivoinvestors.co.uk/bonds.aspx

DISCLAIMER - INTENDED ADDRESSEES

Please note that the information contained in the Prospectus may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Prospectus) only and it is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Prospectus is not addressed. Prior to relying on the information contained in the Prospectus you must ascertain from the Prospectus whether or not you are part of the intended addressees of the information contained therein.

Your right to access this service is conditional upon complying with the above requirement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

PDIEKLFBLXLFBBV

(END) Dow Jones Newswires

March 09, 2022 12:00 ET (17:00 GMT)